Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical Isolates

1 Apr 2025

Abstract excerpt

Lenacapavir (LEN) is a potent, first-in-class long-acting HIV-1 capsid (CA) inhibitor, approved for treatment of people with multi-drug resistant HIV in combination with other antiretrovirals. In clinical studies with LEN, the CA resistance-associated mutations (RAMs) M66I, Q67H/K/N, K70H/N/R/S, N74D/H/K, A105S/T, and T107A/C/N/S were observed. Phenotypic analyses of these CA mutants were possible in single cycle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40223733
DOI: 10.1002/jmv.70340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical IsolatesPMID 40223733Read ↗

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.Semantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirSemantic proximity Read ↗

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.Semantic proximity Read ↗

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.Semantic proximity Read ↗

Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.Semantic proximity Read ↗

Lenacapavir binding to immature Gag triggers the emergence of giant HIV-1 virionsSemantic proximity Read ↗

Rapid HIV-1 genotyping assay for the detection of capsid mutations.Semantic proximity Read ↗

Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to LenacapavirSemantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

HIV-1 gag genotypic resistance testing using short-read and long-read next-generation sequencing technologies.Semantic proximity Read ↗

Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.